Search the website

Search results

18 results

Sort by

List item

Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Macugen (pegaptanib) (PDF/65.01 KB)

authorisation for Macugen (pegaptanib … authorisation for Macugen (pegaptanib … Macugen, INN - pegaptanib 7 Westferry Circus …

First published: 27/07/2011
Last updated: 27/07/2011
EMA/CHMP/563649/2011
List item

Press release: European Medicines Agency: Committee for Medicinal Products for Human Use 12-15 September 2005

CHMP, Last updated: 15/09/2005

applications for � Macugen (pegaptanib sodium), from Pfizer Ltd …
List item

Committee for Medicinal Products for Human Use (CHMP): 18-21 October 2010

European Medicines Agency, London, UK, from 18/10/2010 to 21/10/2010, Last updated: 16/02/2010
List item

Committee for Medicinal Products for Human Use (CHMP): 18-21 July 2011

European Medicines Agency, London, UK, from 18/07/2011 to 21/07/2011, Last updated: 11/06/2010

authorised medicine Macugen (pegaptanib sodium), 0.3 mg solution …
List item

Withdrawal assessment report for Macugen (PDF/2.97 MB)

Macugen INN-pegaptanib sodium 7 Westferry … International Nonproprietary Name: pegaptanib sodium Procedure No … EMEA/H/C/620/II/44 for Macugen (pegaptanib), in the treatment of neovascular …

Adopted
First published: 29/09/2011
Last updated: 29/09/2011
EMA/737688/2011
List item

Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted during the CHMP meeting 21-24 September 2015 (PDF/69.87 KB)

Unlimited validity Macugen, (pegaptanib sodium), PharmaSwiss Ceska …

Adopted
First published: 30/09/2015
Last updated: 30/09/2015
EMA/38595/2015
List item

Committee for Medicinal Products for Human Use (CHMP) - December 2005 plenary meeting monthly report (PDF/578.45 KB)

September 2005 for Macugen (pegaptanib sodium), following post-marketing … intravitreous administration of pegaptanib along with various medications …

First published: 16/01/2006
Last updated: 16/01/2006
EMEA/CHMP/420100/2005, rev 1
List item

Ozurdex-H-C-1140-II-0015 : EPAR - Assessment Report - Variation (PDF/1.9 MB)

Adopted
First published: 15/09/2014
Last updated: 15/09/2014
EMA/492068/2014
List item

European Medicines Agency: Committee for Medicinal Products for Human Use 12-15 September 2005 (PDF/28.93 KB)

applications for � Macugen (pegaptanib sodium), from Pfizer Ltd …

Adopted
First published: 15/09/2005
Last updated: 15/09/2005
EMEA/303099/2005
List item

Committee for Medicinal Products for Human Use (CHMP) - October 2010 plenary meeting monthly report (PDF/298.8 KB)

First published: 28/10/2010
Last updated: 28/10/2010
EMA/CHMP/656448/2010
List item

Eylea : EPAR - Public assessment report (PDF/762.88 KB)

Adopted
First published: 05/12/2012
Last updated: 21/02/2013
EMA/646256/2012 corr
List item

Committee for Medicinal Products for Human Use (CHMP) - February 2006 plenary meeting monthly report (PDF/105.38 KB)

First published: 17/03/2006
Last updated: 17/03/2006
CHMP/70961/2006 Rev.1
List item

Committee for Medicinal Products for Human Use (CHMP) - September 2005 plenary meeting monthly report (PDF/587.86 KB)

this meeting: Macugen (pegaptanib sodium), from Pfizer Ltd …

First published: 28/09/2005
Last updated: 28/09/2005
EMEA/CHMP/295298/2005
List item

Committee for Medicinal Products for Human Use (CHMP) - July 2011 plenary meeting monthly report (PDF/379.86 KB)

authorised medicine Macugen (pegaptanib sodium), 0.3 mg solution …

First published: 29/07/2011
Last updated: 29/07/2011
EMA/CHMP/571474/2011
List item

Eylea-H-C-2392-II-0013 : EPAR - Assessment Report - Variation (PDF/4.15 MB)

Adopted
First published: 20/04/2015
Last updated: 20/04/2015
EMA/CHMP/13670/2015
List item

Lucentis : EPAR - Scientific Discussion (PDF/436.24 KB)

First published: 14/03/2007
Last updated: 14/03/2007
List item

Spinraza : EPAR - Public Assessment Report (PDF/2.18 MB)

Adopted
First published: 21/06/2017
EMA/289068/2017
List item

Withdrawal assessment report for Kyndrisa (PDF/2.67 MB)

Adopted
First published: 06/09/2016
Last updated: 06/09/2016
EMA/439369/2016

18 results

Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Macugen (pegaptanib) (PDF/65.01 KB)

Press release: European Medicines Agency: Committee for Medicinal Products for Human Use 12-15 September 2005

Committee for Medicinal Products for Human Use (CHMP): 18-21 October 2010

Committee for Medicinal Products for Human Use (CHMP): 18-21 July 2011

Withdrawal assessment report for Macugen (PDF/2.97 MB)

Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted during the CHMP meeting 21-24 September 2015 (PDF/69.87 KB)

Committee for Medicinal Products for Human Use (CHMP) - December 2005 plenary meeting monthly report (PDF/578.45 KB)

Ozurdex-H-C-1140-II-0015 : EPAR - Assessment Report - Variation (PDF/1.9 MB)

European Medicines Agency: Committee for Medicinal Products for Human Use 12-15 September 2005 (PDF/28.93 KB)

Committee for Medicinal Products for Human Use (CHMP) - October 2010 plenary meeting monthly report (PDF/298.8 KB)

Eylea : EPAR - Public assessment report (PDF/762.88 KB)

Committee for Medicinal Products for Human Use (CHMP) - February 2006 plenary meeting monthly report (PDF/105.38 KB)

Committee for Medicinal Products for Human Use (CHMP) - September 2005 plenary meeting monthly report (PDF/587.86 KB)

Committee for Medicinal Products for Human Use (CHMP) - July 2011 plenary meeting monthly report (PDF/379.86 KB)

Eylea-H-C-2392-II-0013 : EPAR - Assessment Report - Variation (PDF/4.15 MB)

Lucentis : EPAR - Scientific Discussion (PDF/436.24 KB)

Spinraza : EPAR - Public Assessment Report (PDF/2.18 MB)

Withdrawal assessment report for Kyndrisa (PDF/2.67 MB)